CompanyGraph
Inspire Medical Systems, Inc.
INSP · NYSE Arca · United States
inspiresleep.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.46B, above the global median of $1.15B
- PositionGross margin is 86.5%, higher than 95% of its Medical Devices peers (median 59.2%)
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.46BUSDvs all stocks (USD)
Trailing P/E
11.50xvs Medical Devices peers
Revenue (TTM)
915.25MUSDvs all stocks (USD)
Profit Margin
14.33%vs Medical Devices peers
Beta
0.7110xvs all stocks
52-Week Change
-59.57%vs all stocks
Market Capitalization
1.46BUSDvs all stocks (USD)
Enterprise Value
1.20BUSDvs all stocks (USD)
Trailing P/E
11.50xvs Medical Devices peers
Forward P/E
40.07xvs Medical Devices peers
PEG Ratio
-0.0235xvs Medical Devices peers
Price to Sales (TTM)
1.59xvs Medical Devices peers
Price to Book (MRQ)
1.84xvs Medical Devices peers
Enterprise to Revenue
1.31xvs Medical Devices peers
Enterprise to EBITDA
17.87xvs Medical Devices peers
Gross Margin
86.47%vs Medical Devices peers
Profit Margin
14.33%vs Medical Devices peers
Operating Margin
-0.55%vs Medical Devices peers
Return on Assets (TTM)
3.91%vs Medical Devices peers
Return on Equity (TTM)
18.37%vs Medical Devices peers
Revenue (TTM)
915.25MUSDvs all stocks (USD)
Revenue per Share (TTM)
31.43USDUpdated Jul 19, 2026Quarterly Revenue Growth
1.60%vs Medical Devices peers
Gross Profit (TTM)
785.06MUSDvs all stocks (USD)
EBITDA (TTM)
76.58MUSDvs all stocks (USD)
Net Income (TTM)
131.14MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
136.53MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
85.58MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
911.98MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
133.22MUSDFY2025 · Dec 31, 2025Gross Profit
778.76MUSDFY2025 · Dec 31, 2025Operating Income
50.95MUSDvs all stocks (USD)
Pre-tax Income
65.70MUSDFY2025 · Dec 31, 2025Income Tax Expense
-79.72MUSDFY2025 · Dec 31, 2025Net Income
145.42MUSDFY2025 · Dec 31, 2025EBIT
65.83MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
79.79MUSDFY2025 · Dec 31, 2025Research & Development
103.17MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
624.64MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
17.54MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
137.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
145.42MUSDFY2025 · Dec 31, 2025Operating Cash Flow
107.84MUSDFY2025 · Dec 31, 2025Free Cash Flow
69.35MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
104.81MUSDFY2025 · Dec 31, 2025Interest Paid
137.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
145.42MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
13.96MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-88.75MUSDFY2025 · Dec 31, 2025Stock-based Compensation
130.26MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.11MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-26.23MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-3.75MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-65.17MUSDFY2025 · Dec 31, 2025Capital Expenditures
-38.50MUSDFY2025 · Dec 31, 2025Purchase of Investments
-250.44MUSDFY2025 · Dec 31, 2025Sale of Investments
310.38MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
21.45MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-175.02MUSDFY2025 · Dec 31, 2025Other Financing Charges
-23.04MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-198.06MUSDFY2025 · Dec 31, 2025Shares Outstanding
28.80MSharesUpdated Jul 19, 2026Float Shares
25.47MSharesUpdated Jul 19, 2026Shares Short
4.69MSharesUpdated Jul 19, 2026Short Ratio
4.32daysvs all stocks
Short % of Shares Outstanding
21.35%vs all stocks
% Held by Insiders
1.14%vs all stocks
% Held by Institutions
123.03%vs all stocks
Total Cash (MRQ)
283.83MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.85USDUpdated Jul 19, 2026Total Debt (MRQ)
29.55MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0373xvs Medical Devices peers
Current Ratio (MRQ)
6.34xvs Medical Devices peers
Book Value per Share (MRQ)
27.51USDUpdated Jul 19, 2026Total Assets
907.32MUSDvs all stocks (USD)
Total Current Assets
583.65MUSDFY2025 · Dec 31, 2025Total Liabilities
126.16MUSDFY2025 · Dec 31, 2025Total Non-current Assets
323.67MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
30.10MUSDFY2025 · Dec 31, 2025Total Current Liabilities
96.06MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
104.81MUSDFY2025 · Dec 31, 2025Other Short-term Investments
203.46MUSDFY2025 · Dec 31, 2025Accounts Receivable
119.69MUSDFY2025 · Dec 31, 2025Inventory
145.29MUSDFY2025 · Dec 31, 2025Accounts Payable
36.56MUSDFY2025 · Dec 31, 2025Short-term Debt
2.16MUSDFY2025 · Dec 31, 2025Long-term Debt
30.00MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
104.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
29.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-146.49MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
781.16MUSDvs all stocks (USD)
52-Week Low
38.91USDUpdated Jul 19, 202652-Week High
147.03USDUpdated Jul 19, 202652-Week Change
-59.57%vs all stocks
Beta
0.7110xvs all stocks
50-Day MA
44.38USDUpdated Jul 19, 2026200-Day MA
70.03USDUpdated Jul 19, 2026Avg 10-Day Volume
933.65KSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.04MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
4.40USDUpdated Jul 19, 2026Other Income / Expense
-2.66MUSDFY2025 · Dec 31, 20257 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Is this company growing?
Diagnostic
Total Revenue Growth With Buyback Amplification And Heavy SGA
Revenue is growing and buybacks shrink the share count, so per-share growth runs faster.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 86.5%, higher than 95% of its Medical Devices peers (median 59.2%)Significant
Gross margin: 0.86Industry median: 0.59Industry P95: 0.80Peers compared: 59.00
Return on equity is 18.4%, higher than 95% of its Medical Devices peers (median 2.8%)Significant
Return on equity: 0.18Industry median: 0.03Industry P95: 0.18Peers compared: 59.00
P/E ratio is 11.5×, lower than 95% of its Medical Devices peers (median 35.3×)Notable
P/E ratio: 11.50Industry median: 35.30Industry P5: 16.46Peers compared: 59.00
Structural Tensions
Prioritizing buybacks over growth reinvestmentNotable
Buyback Intensity: 0.12Revenue Growth YoY: 0.02
Financial Health
Altman Z-Score 8.6: safe zoneNotable
Altman Z-Score: 8.60
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.46B, above the global median of $1.15BNotable
Market cap (USD): 1,457,945,541Global Median: 1,146,734,693.424
Revenue is $915.25M, above the global median of $520.53MNotable
Revenue (USD): 915,246,976Global Median: 520,528,949.311
Levered free cash flow is $85.58M, above the global median of $16.24MNotable
Levered free cash flow (USD): 85,575,000Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Vcanbio Cell & Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Xinhua Pharmaceutical Company Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Concord Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRule
HBM Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
KalVista Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Integra LifeSciences Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Jolly Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Olix Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Chongqing Genrix Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Palantir Technologies Inc.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthMulti-Year FCF With Growth And Margin
Harmony Biosciences Holdings, Inc.
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedMulti-Year FCF With Growth And Margin
argenx SE
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital Elevated